Horn Dagmar, Klaas Christoph, Raschke Michael, Stange Richard
Apotheke, Universitätsklinikum Münster, Münster, Deutschland.
Klinik für Unfall‑, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Münster, Münster, Deutschland.
Unfallchirurg. 2019 Jul;122(7):518-525. doi: 10.1007/s00113-019-0685-x.
Due to demographic changes in the population and the development of novel immunosuppressive agents, an increasing number of trauma and orthopedic patients are taking concomitant immunosuppressive medication. These drugs might interfere with the healing process and can possibly retard or prevent wound and fracture healing and lead to a higher risk of infections. In these complex situations a structured and interdisciplinary process during hospital admission should preoperatively evaluate the possibility of interrupting immunosuppressive medications for the perioperative treatment period without risking a relapse of the underlying disease and which surgical approach should be individually selected for the patient.
由于人口结构的变化以及新型免疫抑制剂的发展,越来越多的创伤和骨科患者正在同时服用免疫抑制药物。这些药物可能会干扰愈合过程,并可能延缓或阻止伤口和骨折愈合,导致感染风险增加。在这些复杂情况下,住院期间应采用结构化的跨学科流程,术前评估在不冒基础疾病复发风险的前提下,在围手术期中断免疫抑制药物治疗的可能性,并应为患者单独选择手术方式。